Novartis to acquire Excellergy, adding Phase 1 anti-IgE program
Deal brings Exl-111 into Novartis’s allergy portfolio, targeting IgE-driven diseases including food allergy and asthma.
From stealth to spotlight: with $70m Series A, ‘total allergic control’ is Excellergy's goal
Backed by $70 million in Series A funding, Excellergy emerges from stealth with a mission to lead a new era in immunology - targeting the full IgE pathway to redefine how allergic diseases are treated.